CITATION REPORT List of articles citing

Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/hydralazine: consistency across subgroups in the African-American Heart Failure Trial

DOI: 10.1161/circulationaha.106.644013 Circulation, 2007, 115, 1747-53.

Source: https://exaly.com/paper-pdf/41335962/citation-report.pdf

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
98	Role of the sarcomeric Z-disc in the pathogenesis of cardiomyopathy. <i>Future Cardiology</i> , 2007 , 3, 611-2	2 1.3	19
97	Effects of ACE inhibitors or beta-blockers in patients treated with the fixed-dose combination of isosorbide dinitrate/hydralazine in the African-American Heart Failure Trial. <i>American Journal of Cardiovascular Drugs</i> , 2007 , 7, 373-80	4	13
96	Isosorbide dinitrate and hydralazine in a fixed-dose combination produces further regression of left ventricular remodeling in a well-treated black population with heart failure: results from A-HeFT. <i>Journal of Cardiac Failure</i> , 2007 , 13, 331-9	3.3	60
95	Evidence for the continued safety and tolerability of fixed-dose isosorbide dinitrate/hydralazine in patients with chronic heart failure (the extension to African-American Heart Failure Trial). <i>American Journal of Cardiology</i> , 2007 , 100, 684-9	3	8
94	The genetics of cardiomyopathies: what clinicians should know. <i>Current Heart Failure Reports</i> , 2007 , 4, 229-35	2.8	O
93	Heart failure in African Americans: Earlier onset, different etiologies, and poorer prognosis. <i>Current Cardiovascular Risk Reports</i> , 2008 , 2, 198-202	0.9	
92	Sodium nitroprusside for advanced low-output heart failure. <i>Journal of the American College of Cardiology</i> , 2008 , 52, 200-7	15.1	149
91	Vasodilator therapy for decompensated heart failure. <i>Journal of the American College of Cardiology</i> , 2008 , 52, 208-10	15.1	7
90	Predicting life expectancy in heart failure. <i>JAMA - Journal of the American Medical Association</i> , 2008 , 299, 2566-7	27.4	5
89	Diabetes, left ventricular systolic dysfunction, and chronic heart failure. <i>European Heart Journal</i> , 2008 , 29, 1224-40	9.5	152
88	Early and Sustained Benefit on Event-Free Survival and Heart Failure Hospitalization From Fixed-Dose Combination of Isosorbide Dinitrate/Hydralazine: Consistency Across Subgroups in the African-American Heart Failure Trial. <i>Yearbook of Cardiology</i> , 2008 , 2008, 392-394		
87	Carvedilol Protects Better Against Vascular Events Than Metoprolol in Heart Failure: Results From COMET. <i>Yearbook of Cardiology</i> , 2008 , 2008, 388-392		
86	Effects of fixed-dose isosorbide dinitrate/hydralazine on diastolic function and exercise capacity in hypertension-induced diastolic heart failure. <i>Hypertension</i> , 2009 , 54, 583-90	8.5	28
85	Dysfunctional corin i555(p568) allele is associated with impaired brain natriuretic peptide processing and adverse outcomes in blacks with systolic heart failure: results from the Genetic Risk Assessment in Heart Failure substudy. <i>Circulation: Heart Failure</i> , 2009 , 2, 541-8	7.6	61
84	Isosorbide dinitrate and hydralazine as therapy for African Americans with heart failure; a failed paradigm?. <i>Clinical and Translational Science</i> , 2009 , 2, 309-11	4.9	
83	Usefulness of Isosorbide Dinitrate and Hydralazine as add-on therapy in patients discharged for advanced decompensated heart failure. <i>American Journal of Cardiology</i> , 2009 , 103, 1113-9	3	34
82	The failing diabetic heart: focus on diastolic left ventricular dysfunction. <i>Current Diabetes Reports</i> , 2009 , 9, 79-86	5.6	32

(2011-2009)

81	Pharmacologic management of patients with both heart failure and diabetes. <i>Current Heart Failure Reports</i> , 2009 , 6, 126-32	2.8	3
80	Disease mutations in the "head" domain of the extra-sarcomeric protein desmin distinctly alter its assembly and network-forming properties. <i>Journal of Molecular Medicine</i> , 2009 , 87, 1207-19	5.5	23
79	Relationship of quality of life scores with baseline characteristics and outcomes in the African-American heart failure trial. <i>Journal of Cardiac Failure</i> , 2009 , 15, 835-42	3.3	35
78	Severe myopathy mutations modify the nanomechanics of desmin intermediate filaments. <i>Journal of Molecular Biology</i> , 2009 , 385, 1043-51	6.5	36
77	Management of hypertension in chronic heart failure. <i>Expert Review of Cardiovascular Therapy</i> , 2009 , 7, 423-33	2.5	8
76	The challenges associated with current clinical trials for diastolic heart failure. <i>Current Opinion in Cardiology</i> , 2009 , 24, 230-8	2.1	7
75	Sodium Nitroprusside for Advanced Low-Output Heart Failure. <i>Yearbook of Critical Care Medicine</i> , 2009 , 2009, 69-72		
74	The antiplatelet effects of nitrates: is it of clinical significance in patients with cardiovascular disease?. <i>Cardiology in Review</i> , 2010 , 18, 198-203	3.2	17
73	Cardiac conduction disturbances and differential effects on atrial and ventricular electrophysiological properties in desmin deficient mice. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2010 , 28, 71-80	2.4	19
72	Evolving molecular diagnostics for familial cardiomyopathies: at the heart of it all. <i>Expert Review of Molecular Diagnostics</i> , 2010 , 10, 329-51	3.8	22
71	Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBIS-II) trial. <i>European Journal of Heart Failure</i> , 2010 , 12, 607-16	12.3	50
70	Clinical and genetic issues in dilated cardiomyopathy: a review for genetics professionals. <i>Genetics in Medicine</i> , 2010 , 12, 655-67	8.1	179
69	A novel custom resequencing array for dilated cardiomyopathy. <i>Genetics in Medicine</i> , 2010 , 12, 268-78	8.1	62
68	Neurologic presentations of cardiac disease. <i>Neurologic Clinics</i> , 2010 , 28, 17-36	4.5	
67	Atrial fibrillation and mortality in African American patients with heart failure: results from the African American Heart Failure Trial (A-HeFT). <i>American Heart Journal</i> , 2011 , 162, 154-9	4.9	6
66	Depressive symptoms and poor social support have a synergistic effect on event-free survival in patients with heart failure. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2011 , 40, 492-501	2.6	35
65	Cardiovascular disease in the elderly. Revista Espanola De Cardiologia, 2011, 64, 697-712	1.5	45
64	Cardiovascular Disease in the Elderly. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2011 , 64, 697-712	0.7	3

63	Soluble guanylate cyclase activation with cinaciguat: a new approach to the treatment of decompensated heart failure. <i>Cardiology in Review</i> , 2011 , 19, 23-9	3.2	6
62	Renal function in advanced heart failure. <i>Congestive Heart Failure</i> , 2011 , 17, 180-8		23
61	Future of personalized pharmacotherapy in chronic heart failure patients. <i>Future Cardiology</i> , 2011 , 7, 357-79	1.3	4
60	Treatment of heart failure in African Americansa call to action. <i>Journal of the National Medical Association</i> , 2011 , 103, 86-98	2.3	15
59	Cardiovascular care in an increasingly diverse community. <i>Circulation</i> , 2012 , 125, 1037-42	16.7	3
58	Acute decompensated heart failure - treatments and challenges Circulation Journal, 2012, 76, 532-43	2.9	29
57	Personalized medicine in heart failure: are we there yet?. JACC: Cardiovascular Imaging, 2012, 5, 419-21	8.4	5
56	Effect of fixed-dose combined isosorbide dinitrate/hydralazine in elderly patients in the African-American heart failure trial. <i>Journal of Cardiac Failure</i> , 2012 , 18, 600-6	3.3	14
55	Hypertension in African Americans. 2012 , 25-34		
54	Diagnostic challenge in desmin cardiomyopathy with transformation of clinical phenotypes. <i>Pediatric Cardiology</i> , 2013 , 34, 467-70	2.1	15
53	How can we cure a heart "in flame"? A translational view on inflammation in heart failure. <i>Basic Research in Cardiology</i> , 2013 , 108, 356	11.8	77
52	Desminopathies: pathology and mechanisms. <i>Acta Neuropathologica</i> , 2013 , 125, 47-75	14.3	143
51	Population-based approaches to understanding disparities in cardiovascular disease risk in the United States. <i>International Journal of General Medicine</i> , 2014 , 7, 393-400	2.3	26
50	Asymmetric dimethylarginine, race, and mortality in hemodialysis patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014 , 9, 1426-33	6.9	10
49	Current evidence on treatment of patients with chronic systolic heart failure and renal insufficiency: practical considerations from published data. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 853-71	15.1	8o
48	Adjunctive therapy and management of the transition of care in patients with heart failure. <i>Cardiology Clinics</i> , 2014 , 32, 163-74, x	2.5	4
47	Effect of fixed-dose combination of isosorbide dinitrate and hydralazine on all hospitalizations and on 30-day readmission rates in patients with heart failure: results from the African-American Heart Failure Trial. <i>Circulation: Heart Failure</i> , 2014 , 7, 759-65	7.6	14
46	Targeting the ubiquitin-proteasome system in heart disease: the basis for new therapeutic strategies. <i>Antioxidants and Redox Signaling</i> , 2014 , 21, 2322-43	8.4	41

45	Use of isosorbide dinitrate and hydralazine in African-Americans with heart failure 9 years after the African-American Heart Failure Trial. <i>American Journal of Cardiology</i> , 2014 , 114, 151-9	3	18
44	Acute heart failure in the African American patient. <i>Journal of Cardiac Failure</i> , 2014 , 20, 533-40	3.3	18
43	Exploiting the Pleiotropic Antioxidant Effects of Established Drugs in Cardiovascular Disease. <i>International Journal of Molecular Sciences</i> , 2015 , 16, 18185-223	6.3	48
42	Hypertension in High Risk African Americans. 2015 ,		
41	Heart Failure Morbidity, Mortality, and Its Relationship to Hypertension. 2015, 111-122		
40	Review of heart failure treatment in type 2 diabetes patients: It's at least as effective as in non-diabetic patients!. <i>Diabetes and Metabolism</i> , 2015 , 41, 446-55	5.4	9
39	Management of Heart Failure. 2015 ,		1
38	Desmin in muscle and associated diseases: beyond the structural function. <i>Cell and Tissue Research</i> , 2015 , 360, 591-608	4.2	51
37	Chronic Kidney Disease and Heart Failure 🖟 Nephrologic Approach. 2015 , 560-570		
36	Improving Patient Outcomes With Oral Heart Failure Medications. <i>Home Healthcare Now</i> , 2016 , 34, 242	- 53 5	
35	An evidence-based review of recent advances in therapy for heart failure with reduced ejection fraction (HFrEF). <i>Postgraduate Medical Journal</i> , 2016 , 92, 726-734	2	7
34	Introduction Hereditary Cardiomyopathies. 2016 , 51-59		
33	New Novel Treatment Approaches for Heart Failure With Reduced Ejection Fraction. <i>Journal of Pharmacy Practice</i> , 2017 , 30, 541-548	1.3	
32	Current insights into LMNA cardiomyopathies: Existing models and missing LINCs. <i>Nucleus</i> , 2017 , 8, 17-2	3 3 .9	42
31	Heart Failure and Kidney Disease. Advances in Experimental Medicine and Biology, 2018, 1067, 219-238	3.6	12
30	Novel trigenic CACNA1C/DES/MYPN mutations in a family of hypertrophic cardiomyopathy with early repolarization and short QT syndrome. <i>Journal of Translational Medicine</i> , 2017 , 15, 78	8.5	18
29	BIDIL: A RACE-TARGETED DRUG FOR BLACK AMERICANS ONLY. <i>Asian Journal of Pharmaceutical and Clinical Research</i> , 2017 , 10, 11	0.4	
28	Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2018 , 20, 853-872	12.3	264

27	Renal function monitoring in heart failure - what is the optimal frequency? A narrative review. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 5-17	3.8	8
26	Inorganic nitrite and nitrate in cardiovascular therapy: A better alternative to organic nitrates as nitric oxide donors?. <i>Vascular Pharmacology</i> , 2018 , 102, 1-10	5.9	41
25	Correlates of Self-Care Behaviors in Adults With Type 2 Diabetes and Comorbid Heart Failure. <i>The Diabetes Educator</i> , 2019 , 45, 380-396	2.5	6
24	Dilated cardiomyopathy. <i>Nature Reviews Disease Primers</i> , 2019 , 5, 32	51.1	143
23	Treatment of Patients with Heart failure and Type 2 Diabetes: a review of the literature. <i>Italian Journal of Medicine</i> , 2019 , 13, 205-224	0.5	
22	Atrial Fibrillation-Mediated Cardiomyopathy. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2019 , 12, e007809	6.4	7
21	Chronic Kidney Disease and Heart Failure A Nephrologic Approach. 2020, 883-897		
20	Heart Failure: A Palliative Medicine Review of Disease, Therapies, and Medications With a Focus on Symptoms, Function, and Quality of Life. <i>Journal of Pain and Symptom Management</i> , 2020 , 59, 1127-114	16 ^{4.8} 1	1
19	Consenso de expertos sobre la insuficiencia cardiaca con fraccifi de eyeccifi reducida: mb allude las gulls. <i>Revista Espanola De Cardiologia Suplementos</i> , 2020 , 20, 1-46	0.2	2
18	Pharmacological interventions for heart failure in people with chronic kidney disease. <i>The Cochrane Library</i> , 2020 , 2, CD012466	5.2	3
17	Intermediate filament diseases: desminopathy. <i>Advances in Experimental Medicine and Biology</i> , 2008 , 642, 131-64	3.6	75
16	Review of Heart Failure Management in African-Americans. 2015 , 277-286		1
15	The Limitations of Symptom-based Heart Failure Management. Cardiac Failure Review, 2019, 5, 74-77	4.2	4
14	Disparities in cardiovascular disease risk in the United States. Current Cardiology Reviews, 2015, 11, 238	-4 5 ₄	176
13	Diabetic cardiomyopathy: Pathophysiology, theories and evidence to date. <i>World Journal of Diabetes</i> , 2019 , 10, 490-510	4.7	34
12	Updated Cardiovascular Prevention Guideline of the Brazilian Society of Cardiology - 2019. <i>Arquivos Brasileiros De Cardiologia</i> , 2019 , 113, 787-891	1.2	29
11	Heart Failure in Racial/Ethnic Groups. 2009 , 269-296		
10	Heart Failure. 2010 , 1036-1053		

CITATION REPORT

9

8 Heart Disease in Varied Populations. 2012, 21-29

7 Pregnancy in a patient with cancer and heart failure: challenges and complexities. Journal of the Advanced Practitioner in Oncology, 2012, 3, 85-93

6 The Role of Clinical Observation: Red Flag 1 [Cardiomyopathies and Skeletal Muscle Involvement. 2013, 25-42

5 The Role of Clinical Observation: Red Flag 2 [Cardiomyopathies and Arrhythmias. 2013, 43-49

4 Acute Decompensated Cardiac Failure. 2015, 445-470

3 Induced Pluripotent Stem Cells in Familial Dilated Cardiomyopathy. Pancreatic Islet Biology, 2015, 11-28 0.4

2 Tratamiento de la insuficiencia cardiaca en el paciente con insuficiencia renal avanzada. Revista Espanola De Cardiologia Suplementos, 2019, 18, 31-39

Evidence-Based Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction and

Cardiomyopathy, Sarcomeropathy, and Z-diskopathy. 2011, 225-234

Chronic Kidney Disease.. Circulation, 2022, 145, 693-712

16.7 6